Hämostaseologische Krankheitsbilder auf der Intensivstation

I. Scharrer

doi:10.1055/s-0037-1619654

Hämostaseologie, Table of Contents

Hamostaseologie 2005; 25(02): 200-204
DOI: 10.1055/s-0037-1619654

Original Article

Schattauer GmbH

Hämostaseologische Krankheitsbilder auf der Intensivstation

TTP, HUS, FVIII-Hemmkörperhämophilie und katastrophales APS-SyndromHaemostaseological diseases on the intensive care unitsTTP, HUS, spontaneous acquired FVIII inhibitor haemophilia and catastrophic antiphospholipide syndrome

I. Scharrer

¹Hämostaseologie (Leiterin: Prof. Dr. med. Inge Scharrer), J.W. Goethe Universitätskliniken Frankfurt am Main

› Author Affiliations

Abstract

Zusammenfassung

Ein kleiner Teil der Intensivpatienten leiden an akuten hämostaseologischen Erkrankungen mit sehr schlechter Prognose. Zu diesen Notfallerkrankungen zählen die thrombotisch-thrombozytopenische Purpura (TTP), das hämolytisch-urämische Syndrom (HUS), die erworbene Hemmkörperhämophilie und das Catastrophic-Antiphospholipid-Syndrom (CAPS). Diese Patienten benötigen eine sehr schnelle Diagnostik und eine sofortige Therapie.

Summary

A minority of patients presenting with acute life threatening syndromes characterized by severe bleeding episodes or microvascular thromboses on the intensive care unit. Especially patients with TTP, HUS, acquired haemophilia and CAPS have a poor prognosis. These emergency cases require a rapid diagnosis and an immediate onset of treatment.

Schlüsselwörter

TTP - HUS - FVIII-Hemmkörperhämophilie - CAPS

Keywords

TTP - HUS - spontaneous acquired FVIII inhibitor haemophilia - CAPS

Full Text

References

Literatur
1 Asherson RA, Cervera R, de Groot PG. et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-4.
2 Bell WR, Braine HG, Ness PM. et al. Improved survival in thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome clinical experience in 108 patients. N Engl. J Med. 1991; 325: 398-403.
3 Bennett C, Connors JM, Carwile JM. et al. Thrombotic thrombocytopenic purpura associated with Clopidogrel. N Engl J Med 2000; 342: 1773-7.
4 Chemnitz J, Draube A, Scheid C. et al. Successful Treatment of Severe Thrombotic Thrombocytopenic Pupura With the Monoclonal Antibody Rituximab. American Journal of Hematology 2002; 71: 105-8.
5 Chierichini A, Foddai AL, Vittoi MA. et al. High dose dexametasone given along with plasma exchange as treatment of thrombotic thrombocytopenic pupura (TTP): Results of a single centre experience. Blood. 2003 102 II, 131b, Abstr. 4233.
6 Cohen AJ, Kessler CM. Acquired inhibitors. Baill Clin Haemat 1996; 9: 331-54.
7 Ducloy-Bouthors AS, Caron C, Subtil D. et al. Thrombotic thrombocytopenic pupura: Medical and biological monitoring of six pregnancies. Eur J Obst Gynecol Reprod Biol 2003; 111: 146-52.
8 Ferrara F, Annunziata M, Pollio F. et al. Vincristine as treatment for recurrent episodes of thrombotic thrombocytopenic purpura. Ann Hematol 2002; 81: 7-10.
9 Fujikawa K, Suzuki H, McMullen B. et al. Purification of human von-Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001; 98: 1662-6.
10 Furlan M, Robles R, Gallbusera M. et al. Von-Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 1998; 339: 1578-84.
11 Furlan M, Robles R, Lämmle B. Partial purification and characterization of protease from human plasma cleaving von-Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-34.
12 Gaddis TG, Guthrie TH, Drew MJ. Treatment of plasma refractory thrombotic thrombocytopenic purpura with protein A immunoabsorption. Am J Hematol 1997; 55: 55-8.
13 Gasser C, Gautier E, Steck A. et al. Hämolytisch-Urämisches Syndrom: bilaterale Nierenrindennekrosen bei akuten erworbenen hämolytischen Anämien. Schweiz Med Wochenschr 1955; 85: 905-9.
14 Gerritsen HE, Robles R, Lämmle B. et al. Partial amino acid sequence of purified von-Willebrand factor-cleaving protease. Blood 2001; 98: 1654-61.
15 Giles AR, Verbruggen B, Rivard GE. et al. and the Association of Hemophilia Centre Directors of Canada. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the hemophilia A population of Canada. Thromb Haemost 1998; 79: 872-5.
16 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
17 Green D, Rademaker AW, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies. Thromb Haemost 1993; 70: 753-7.
18 Hay CRM, Negrier C, Ludlam CA. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicenter study. Thromb Haemost 1997; 78: 1463-7.
19 Hay CRM. Acquired haemophilia. Baill Clin Haemat 1998; 11: 287-303.
20 Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19: 163-76.
21 Hedner U. Dosing and monitoring NovoSeven treatment. Haemostasis 1996; 26: 102-8.
22 Huhmann I, Lechner K. Spontane Faktor-VIII-Inhibitoren. Hämostaseologie 1996; 16: 164-70.
23 Kasper CK, Aledort LM, Counts RB. et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-72.
24 Kessler CM, Ludlam CA. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. Semin Hematol 1993; 30 (Suppl. 01) 22-7.
25 Kitchens CS. Thrombotic storm: when thrombosis begets thrombosis. Am J Med 1998; 104: 381-5.
26 Knöbl P, Derfler K, Korninger L. et al. Elimination of acquired factor VIII antibodies by extracorporal antibody-based IA (Ig-Therasorb). Thromb Haemost 1995; 74: 1035-8.
27 Koschmieder S, Miesbach W, Fauth F. et al. Combined plasmapheresis and immunosuppression as rescue treatment of a patient with catastrophic antiphospholipid syndrome occurring despite anticoagulation: a case report. Blood Coagul Fibrinolysis 2003; 14: 395-9.
28 Krause M, Betz C, Stier-Brück I. et al. Rituximab – A new Treatment of Acquired Hemophilia A ?. In: Scharrer I, Schramm W. (Hrsg). 33^rd Hemophilia Symposium Hamburg 2002. Heidelberg: Springer; 2004: 35-7.
29 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-94.
30 Michiels JJ, Bosch Lj, van der Plas PM. et al. Factor VIII-inhibitor postpartum. Scand J Coll Haematol 1978; 20: 97-107.
31 Miesbach W, Scharrer I, Asherson RA. Recurrent life-threatening thromboembolism and catastrophic antiphospholipid syndrome in a patient despite sufficient oral anticoagulation. Clin Rheum 2004; 23: 256-61.
32 Moake JL, Rudy CK, Troll JH. et al. Unusually large plasma factor VIII: von-Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982; 307: 1432-5.
33 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: A hitherto undescribed disease. Proc NY Pathol Soc 1924; 24: 21-4.
34 Negrier C, Goudeman J, Sultan Y. et al. and the members of the French FEIBA study group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
35 Scharrer I. Erworbene Inhibitoren gegen Faktor IX. Hämostaseologie 1996; 16: 171-3.
36 Schulman I, Pierce M, Lukens A. et al. Studies on thrombopoiesis: I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency. Blood 1960; 16: 943-57.
37 Stasi R, Brunetti M, Stipa E. et al. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004; 103: 4424-8.
38 Taylor CM. Complement factor H and the haemolytic uraemic syndrome. Lancet 2001; 358: 1200-2.
39 Torok TJ, Holman RC, Chorba TL. Increasing mortality from thrombotic thrombocytopenic purpura in the United States – Analysis of national mortality data 1968–1991. Am J Hematol 1995; 50: 84-90.
40 Tsai HM. Physiologic cleavage of von-Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ions. Blood 1996; 87: 4235-44.
41 Upshaw Jr. JD. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia. N Eng J Med 1978; 298: 1350-2.
42 Wenke A, Aygören-Pürsün E, Ehrenforth S. et al. Verlauf bei 13 Patienten mit erworbener Hemmkörperhämophilie. In: Scharrer I, Schramm W. (Hrsg). 29. Hämophilie Symposion Hamburg 1998. Heidelberg: Springer; 1999: 247-52.
43 Zakarija A, Bandarenko N, Pandey Dilip K. et al. Clopidogrel associated TTP: Clinical characteristics and predictors of survival. Blood. 2003 102 I, 593a, Abstr. 1977.
44 Zeitler H, Unkrig C, Brackmann H. et al. An immunomodulatory treatment of acquired hemophilia A with longterm IgG IA, immunosuppressing, and antigen substitution – a modified Bonn protocol inducing immune tolerance. Blood 1997; 90 (Suppl. 01) 36A.
45 Zheng X, Pallers A, Lawrence T. et al. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med 1003; 138: 105-8.